GRAIL Inc. Common Stock (GRAL)

About GRAL

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, inc…

Sector

Health Care

Industry

Medical Specialities

Employees

910

Website

grail.com/

Fundamentals

1-day range

$77.7$80.99

Market cap

$3.02B

P/E (trailing)

—

P/E (forward)

-8.11

EPS (trailing)

$-9.75

Dividend yield

—

Beta

1.64

Avg. volume

704.3K

Forecasts

8 analyst ratings

GRAIL Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• GRAL

  GRAIL Inc. Common Stock

  $79.94

  ▼ 3.10%
  Market cap $3.02BP/E —
  $30.82$118.84
• ALHC

  Alignment Healthcare Inc. Common Stock

  $13.62

  ▲ 0.44%
  Market cap $3.02BP/E 68.60
  $12.7$25.12
• CDNA

  CareDx Inc. Common Stock

  $49.73

  ▼ 5.02%
  Market cap $2.48BP/E 22.08
  $12.37$53.67
• VCYT

  Veracyte Inc. Common Stock

  $43.36

  ▼ 4.19%
  Market cap $3.58BP/E 29.24
  $28.25$60.91
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $1.99BP/E —
  $13.18$34.29
• FTRE

  Fortrea Holdings Inc. Common Stock

  $18.81

  ▼ 0.27%
  Market cap $1.80BP/E —
  $8.31$21.39
• CELC

  Celcuity Inc. Common Stock

  $88.46

  ▼ 5.13%
  Market cap $4.28BP/E —
  $44.42$151.02

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Hedging Exposure In This Volatile Market
  SeekingAlpha · 8/20/2026
• GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting
  Yahoo · 8/14/2026
• GRAIL (GRAL) Q2 2026 Earnings Call Transcript
  Yahoo · 8/13/2026
• GRAIL: Looking Beyond The NHS-Galleri Headline
  SeekingAlpha · 8/12/2026
• Guardant Health: Screening And MRD Are Just Getting Started
  SeekingAlpha · 8/11/2026
• FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test
  Benzinga · 8/10/2026
• Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?
  Yahoo · 8/8/2026
• GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
  Yahoo · 8/7/2026

• William J. Chase · July 15, 2026 · Grant

  276 @ $74.36
• Steven Mizell · July 15, 2026 · Grant

  268 @ $74.36
• Gregory L. Summe · July 15, 2026 · Grant

  427 @ $74.36
• Sarah Krevans · June 18, 2026 · Grant

  5.5K @ $63.74
• William J. Chase · June 18, 2026 · Grant

  5.5K @ $63.74
• Steven Mizell · June 18, 2026 · Grant

  5.5K @ $63.74
• Gregory L. Summe · June 18, 2026 · Grant

  5.5K @ $63.74
• Andrew John Partridge · June 4, 2026 · Sale

  1.5K @ $61.08
• Joshua J. Ofman · June 3, 2026 · Grant

  3.2K @ $61.13
• Joshua J. Ofman · June 1, 2026 · Grant

  27.9K @ $64.4
• William J. Chase · April 15, 2026 · Grant

  408 @ $49.79
• Steven Mizell · April 15, 2026 · Grant

  396 @ $49.79
• Gregory L. Summe · April 15, 2026 · Grant

  631 @ $49.79
• Aaron Freidin · April 8, 2026 · Sale

  45.8K @ $49.92
• Joshua J. Ofman · April 8, 2026 · Sale

  61.7K @ $49.92

Institutional Ownership

March 31, 2026

Total shares held

36.58M

Total value held

$1.89B

Institutional holders

358